S
CYTK icon

SignatureFD’s Cytokinetics CYTK Stock Holding History

SignatureFD’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.7K Buy
1,135
+247
+28% +$17.7K ﹤0.01% 1473
2026
Q1 		$58.5K Buy
888
+261
+42% +$16.6K ﹤0.01% 1641
2025
Q4 		$39.8K Buy
627
+56
+10% +$3.48K ﹤0.01% 1782
2025
Q3 		$31.4K Buy
571
+54
+10% +$2.23K ﹤0.01% 1888
2025
Q2 		$17.1K Buy
517
+2
+0.4% +$70 ﹤0.01% 2123
2025
Q1 		$20.7K Buy
515
+51
+11% +$2.34K ﹤0.01% 2038
2024
Q4 		$21.8K Sell
464
-55
-11% -$2.86K ﹤0.01% 2020
2024
Q3 		$27.4K Sell
519
-42
-7% -$2.34K ﹤0.01% 1890
2024
Q2 		$30.4K Sell
561
-194
-26% -$11.7K ﹤0.01% 1761
2024
Q1 		$52.9K Buy
755
+332
+78% +$25.7K ﹤0.01% 1520
2023
Q4 		$35.3K Sell
423
-32
-7% -$1.16K ﹤0.01% 1644
2023
Q3 		$13.4K Buy
455
+324
+247% +$10.8K ﹤0.01% 2051
2023
Q2 		$4.27K Buy
131
+88
+205% +$3.26K ﹤0.01% 2569
2023
Q1 		$1.51K Sell
43
-14
-25% -$571 ﹤0.01% 2880
2022
Q4 		$2.61K Buy
57
+3
+6% +$129 ﹤0.01% 2722
2022
Q3 		$3K Sell
54
-17
-24% -$818 ﹤0.01% 2624
2022
Q2 		$3K Buy
+71
New +$2.86K ﹤0.01% 2607

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's CYTK Position: Q2 2026 in Review

SignatureFD increased its Cytokinetics (CYTK) stake by 28% in Q2 2026, buying an estimated $17.7K and bringing the position to 1,135 shares worth $96.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

SignatureFD first reported a position in CYTK in Q2 2022 and has held it in 17 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • SignatureFD held 1,135 shares of Cytokinetics worth $96.7K as of Q2 2026.
  • SignatureFD bought 247 Cytokinetics shares in Q2 2026, an estimated $17.7K.
  • Cytokinetics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1473 holding.
  • SignatureFD first reported a position in Cytokinetics in Q2 2022 and has held it in 17 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.